US1511902041 - Common Stock
Which stocks have an unusual volume on Friday?
Celularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidance of $50 Million to $56...
Celularity common stock and warrants will continue to trade on The Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively...
FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, has...
FLORHAM PARK, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing and...
FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today...
FLORHAM PARK, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company...
Seasoned Public Company Director and Finance Veteran Brings Extensive Track Record of Success in Facilitating the Growth of Shareholder Value...
FLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative and cellular medicine company...
FLORHAM PARK, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced its 2023 full-year reported combined net sales of its advanced biomaterial product and biobanking businesses and announced first half 2024 expected combined net sales. As used here, “net sales” refers to direct-customer and distributor product sales of advanced biomaterial products and biobanking services, respectively, and does not include any revenue from other sources such as fees or revenue earned under research collaboration agreements.
Company presents results from in vivo studies of PT-CD16VS, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells, in combination with various monoclonal antibodies
Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the ASCO Annual Meeting...
FLORHAM PARK, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing...
Placental T Cells Demonstrated Greater Persistence, Resistance to Exhaustion and Efficacy Compared To Peripheral Blood Mononuclear Cells...
Event Will Be Hosted On-site and Aired Virtually Highlighting Research, Clinical and Commercial Progress
Event Will Be Hosted On-site and Aired Virtually Highlighting Research, Clinical and Commercial Progress...
FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (the “Company”), a regenerative medicine company developing...
FLORHAM PARK, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative medicine company developing...
Company Presenting at ASGCT Annual Meeting...
Nationally Established Q Code Will Further Support the Use of Biovance® 3L by Physicians to Treat Wound Care Patients in Office Settings...
Company Has Already Received IND Clearance from the FDA and Plans to Begin Phase 1/2 Study in 2024 with Off-the-Shelf, Placental-Derived Cell Therapy...
Presentation Will Discuss Cellular Immunotherapy’s Potential Role in Treating Chronic Conditions and Extending People’s Lives...
Keynote Will Discuss Cellular Immunotherapy’s Potential for Treating Chronic Conditions, Including Cancer, Multiple Sclerosis and Parkinson’s Disease...
Company presenting an in vivo study of PT-CD16, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells at...
FLORHAM PARK, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Celularity, Inc. (Nasdaq: CELU; CELUW) (“Celularity”), a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of its Class A common stock, to be effective at 5:00 p.m. Eastern Standard Time, Wednesday, February 28, 2024. Celularity’s Class A common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Thursday, February 29, 2024, under the current trading symbol, “CELU.” The reverse stock split was approved by Celularity’s stockholders on February 22, 2024, and is intended to increase the per share trading price of its Class A common stock to enable Celularity to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Continuing the substantial growth trajectory that began during 2023, for the first quarter 2024 and the full year 2024, Celularity expects triple-digit...
Celularity closed two financing transactions on January 16, 2024, totaling $21 million in gross proceeds, consisting of a $6 million private placement with...